Andrew Holden (Auckland, New Zealand) presents the latest results from the IN.PACT™ AV Access trial (Medtronic), which indicate “outstanding” target-lesion primary patency rates of 52.2% through 24 months in dialysis patients with dysfunctional arteriovenous fistulas (AVFs), offering a “highly-significant advantage” over standard balloon angioplasty procedures. These findings were announced in a podium 1st presentation at the Charing Cross (CX) 2021 Digital Edition (19–22 April, online).
Holden, who is director of interventional radiology at Auckland Regional Public Health Service and the trial’s presenting author, stated that the IN.PACT™ AV drug-coated balloon (DCB) met its primary safety and effectiveness endpoints after 24 months—including demonstrating “absolutely no difference” in all-cause mortality rates between the trial’s DCB and standard percutaneous transluminal angioplasty (PTA) arms.
Presenting the longer-term patency results through 24 months, Holden said it was “very pleasing to see” a flattening of the Kaplan-Meier curves in both the DCB and standard PTA arms of the trial—as well as a target-lesion patency rate of 52.2% in the DCB group. He added that a “highly-significant advantage” was observed compared to the PTA group, which demonstrated a patency rate of 36.2% through 24 months.
This video is sponsored by Medtronic.